

## **REMARKS**

Claims 1, 3-8, 10-13 and 17-25 will be pending upon entry of the presently made amendments.

Claims 4, 6 and 18-25 are withdrawn from consideration as being drawn to a non-elected invention.

Claims 9 and 14-16 have been canceled without prejudice.

Claim 1 has been amended without prejudice to recite that the cancer is treatable by the inhibition of more than one protein kinase. Support for this amendment is found in the specification as filed at least at page 14, lines 3-6.

Claims 10 and 17 have been amended to depend from claim 1.

Claims 1 and 13 have been amended to replace the term “modulated” with “inhibited.” Support for these amendments is found in the specification as filed at least at page 19, lines 19-21.

No new matter has been added.

Applicants reserve the right to prosecute the subject matter of any amended, canceled or withdrawn claim or any unclaimed subject matter in one or more related applications.

### **I.     The Rejection of Claims 1-3, 5 and 7-17 Under 35 U.S.C. 112, First Paragraph**

Claims 1, 3, 5 and 7-17 remain rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. In particular, the Examiner has stated that the specification does not enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Applicants respectfully traverse this rejection.

In response to Applicants’ arguments, the Examiner has noted that Force *et al.* states that compounds showing high activity and specificity *in vitro* may show markedly different and even unexpectedly nonspecific activity *in vivo*. In addition, while acknowledging that Manning *et al.* teaches a role of JNK in cancer, the Examiner has stated that Manning *et al.* does not teach that every modulator of JNK activity will treat all cancers.<sup>1</sup>

Preliminarily, Applicants note that the claims have been amended to recite methods for treating cancer treatable by the inhibition of more than one protein kinase. In other words, the pending claims are not directed to the treatment of *all* cancers, but are instead directed to the treatment of a focused subset of cancers that are treatable by the inhibition of

---

<sup>1</sup> Applicants note that the present claims are directed to the treatment of cancer by the inhibition of multiple kinases and not solely to the inhibition of JNK.

multiple kinases. In addition, the claims are not directed to every modulator of JNK activity, but instead recite a focused class of chemical compounds with a well-defined core structure as inhibitors of multiple kinases.

Nevertheless, Applicants again respectfully submit that the possibility that some compounds within the scope of the class of compounds recited in the pending claims may not be effective *in vivo* does not preclude patentability. *Scott v. Finney*, 34 F.3d 1058, 1063 (Fed. Cir. 1004) (“Testing for full safety and effectiveness...is more properly left to the [FDA]”); *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1564 (Fed. Cir. 1996) (“Of course, it is possible that some compounds active *in vitro* may not be active *in vivo*”). Indeed, it is well-established that an applicant need not have actually reduced an invention to practice prior to filing. *Gould v. Quigg*, 822 F.2d 1074, 1078 (Fed. Cir. 1987).

Applicants respectfully point the Examiner to the decision in *In re Bundy* wherein the United States Court of Customs and Patent Appeals held that all that is necessary to satisfy the how-to-use (*i.e.*, enablement) requirement of 35 U.S.C. § 112 is the disclosure of some activity coupled with the knowledge as to the use of this activity. *In re Bundy*, 642 F.2d 430, 434 (C.C.P.A. 1981). In particular, the Court held that claims can be enabled notwithstanding the absence of examples of dosages for human use or animal tests. *Id.* (held that applicant’s disclosure that novel prostaglandins had certain pharmacological properties and possessed activity similar to known prostaglandins was sufficient to enable one skilled in the art). In explaining its reasoning, the Court stated that the early filing of an application with its disclosure of novel compounds which possess significant therapeutic use is to be encouraged. *Id.* The Court further stated that specific testing of thousands of compounds...in order to satisfy 35 U.S.C. § 112 would delay disclosure and frustrate, rather than further, the interests of the public and noted that one skilled in the art would know how to use the compounds to determine the specific dosages for the various biological purposes. *Id.* Accordingly, Applicants respectfully submit that the claims are enabled because the specification teaches compounds that have activity against multiple kinases, provides assays for measuring the activity of compounds against numerous kinases and further provides a nexus between kinase inhibition and the treatment of cancer (which is further evidenced by the previously provided peer-reviewed publications by Force *et al.* and Manning *et al.*).

Regarding the Examiner’s statement with respect to the “speculative” and “sufficiently unusual” nature of the claimed use, Applicants respectfully submit that the Federal Circuit has specifically stated that the treatment of cancer with chemical compounds

does not suggest an unbelievable undertaking or involve implausible scientific principles. *In re Brana*, 51 F.3d 1560, 1566 (Fed. Cir. 1995).

The Examiner has further alleged that undue experimentation would be required for one skilled in the art to practice the claimed invention. In particular, the Examiner has stated that one would have to determine a useful model that correlates with clinical efficacy, a dosage range and a route of administration. As the Examiner is aware, experimentation is not necessarily undue because it is complex, time consuming or expensive. *United States v. Telectronics, Inc.*, 857 F.2d 778, 785 (Fed. Cir. 1988) (studies costing \$50,000 and taking 6-12 months to complete failed to show undue experimentation); M.P.E.P. § 2164.06. With respect to the availability of a useful model that correlates with clinical efficacy, Applicants respectfully submit that such models are well known in the art and that it is well established that the specification need not teach, and preferably omits, what is well known in the art. *Hybritech Inc. v. Monoclonal Antibodies*, 802 F.2d 1367, 1385 (Fed. Cir. 1986).

The Examiner has further stated that if the model, dosage range or route of administration failed, one would have to start over again to determine suitable methods, dosage ranges and routes of administration in which to determine if the compounds will work to treat cancer. Applicants respectfully submit that such is the nature of experimentation and it has been held that requiring disclosure which would enable one skilled in the art to determine an outcome, with reasonable certainty before performing the experiment would result in all experimentation being "undue," since the term "experimentation" implies that the success of the particular activity is uncertain. *Application of Angstadt*, 537 F.2d 498, 503 (C.C.P.A. 1976). Furthermore, the Federal Circuit has held that a specification is enabling in part because those skilled in the art would know how to conduct a dose response study to determine the appropriate amounts to be used. *Merck & Co., Inc. v. Biocraft Laboratories, Inc.*, 874 F.2d 804, 809 (Fed. Cir. 1989).

In summary, Applicants submit that the disclosure of the present application, in combination with what is known in the art regarding small molecule kinase inhibitors, satisfies the enablement requirement of 35 U.S.C. § 112, first paragraph. Specifically, the present application provides small molecule kinase inhibitors (wherein the Examiner has acknowledged that the specification is enabling for determining the activity of various indazole compounds that inhibit, modulate or regulate tyrosine kinase signal transduction) and the literature demonstrates not only that kinases are accepted therapeutic targets for cancer, but that a significant number of clinical trials directed to the use of small molecule

kinase inhibitors as anti-cancer agents are currently ongoing. Thus, it is within the means of those skilled in the art to practice the present claims without undue experimentation.

Accordingly, Applicants respectfully submit that the rejection of claims 1, 3, 5 and 7-17 under 35 U.S.C. § 112, first paragraph, has been overcome and should be withdrawn.

## **II.     The Rejection of Claims 1-3, 5 and 7-17** **Under 35 U.S.C. 112, First Paragraph**

Claims 1, 3, 5 and 7-17 remain rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. In particular, while acknowledging that the specification is enabling for determining the activity of various indazole compounds that inhibit, modulate or regulate tyrosine kinase signal transduction, the Examiner has stated that it does not reasonably provide enablement for the treatment of all cancers with the indazole compounds.

As discussed above, Applicants note that the pending claims do not recite the treatment of all cancers. Rather, the claims as amended recite the treatment of cancer treatable by the inhibition of more than one protein kinase.

Accordingly, for the same reasons set forth above, Applicants respectfully submit that the rejection of claims 1, 3, 5 and 7-17 under 35 U.S.C. § 112, first paragraph, has been overcome and should be withdrawn.

## **III.    Provisional Double Patenting**

Claims 1, 3 and 14-17 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being allegedly unpatentable over claims 1-2 and 9-10 of co-pending U.S. Application No. 11/512,836 (the “’836 application”) and claims 1-14 of co-pending U.S. Application No. 11/376,786 (the “’786 application”). Per M.P.E.P § 804, a provisional double patenting rejection should continue to be made unless it is the sole remaining rejection in one of the applications. Upon entry of the presently made amendment and remarks, Applicants believe that the sole remaining rejections in the present application will be the provisional double patenting rejections over the ’836 and ’786 applications. Applicants will consider filing a terminal disclaimer in connection with the ’836 and ’786 applications. Accordingly, Applicants respectfully request that the provisional double patenting rejection over the ’836 and ’786 applications be withdrawn.

### CONCLUSION

Applicant respectfully requests that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response other than that due in connection with the Petition for Extension of Time; however, in the event that any additional fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: September 11, 2008

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*  
*By: Michael J. Bruner, Reg. No. 47,458*

By: Michael J. Bruner (Reg. No. 47,458)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**

12265 El Camino Real, Suite 200

San Diego, California 92130

(858) 314-1130